274 related articles for article (PubMed ID: 31545446)
1. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
3. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of
Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
[TBL] [Abstract][Full Text] [Related]
5. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
6. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
7. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
8. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
[TBL] [Abstract][Full Text] [Related]
9. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.
Sial N; Ahmad M; Hussain MS; Iqbal MJ; Hameed Y; Khan M; Abbas M; Asif R; Rehman JU; Atif M; Khan MR; Hameed Z; Saeed H; Tanveer R; Saeed S; Sharif A; Asif HM
Sci Rep; 2021 Oct; 11(1):19873. PubMed ID: 34615943
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
Front Immunol; 2018; 9():997. PubMed ID: 29867974
[TBL] [Abstract][Full Text] [Related]
11. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
14. Collagen Triple Helix Repeat Containing 1 Expression in Osteosarcoma: A New Predictor of Prognosis.
Liu Y; Abulimiti N; Wang C
Ann Clin Lab Sci; 2018 May; 48(3):338-344. PubMed ID: 29970438
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis.
Chen YL; Wang TH; Hsu HC; Yuan RH; Jeng YM
PLoS One; 2013; 8(7):e70324. PubMed ID: 23922981
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
[TBL] [Abstract][Full Text] [Related]
18. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
[TBL] [Abstract][Full Text] [Related]
19. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
[TBL] [Abstract][Full Text] [Related]
20. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
